Kru¨ppel-like factor 2 (KLF2) is a member of the KLF family of zinc-finger transcription factors and is involved in maintaining T-cell quiescence, regulating preadipocyte differentiation, endothelial cell function and lung development. We used a tetracycline-inducible system in Jurkat T leukemia cells to study the biological role of KLF2 in cellular growth and differentiation. Our results show that expression of KLF2 inhibits cell growth in autonomously proliferating Jurkat cells. Further, 3 H-thymidine uptake assays indicate that KLF2 inhibits DNA synthesis in these cells. Moreover, both activation and inhibitory domains are required for KLF2 to suppress Jurkat cell proliferation. In addition, KLF2 upregulates p21 WAF1/CIP1 expression. Additionally, we found that KLF2 upregulates p21 WAF1/CIP1 promoter activity in Jurkat, HepG2 and SW480 cells. Our analysis shows that the potential KLF2 responsive elements are located between À124 and À60 of the p21 WAF1/CIP1 promoter. The sole CACCC site, a sequence recognized by KLF2, in this region is not the element responsive to KLF2. Finally, we determined that the Sp1-3-binding site is the functional responsive element of KLF2 in the p21 WAF1/CIP1 promoter, and we conclude that KLF2 directly regulates p21 WAF1/CIP1 expression.
Introduction
Lung Kru¨ppel-like factor (LKLF, now termed KLF2) is a member of the closely related family of the Kru¨ppel-like factors (KLFs). It is composed of activation and inhibitory domains and, therefore, can activate or repress transcription of target promoters (Conkright et al., 2001) . Members of the KLF family, such as KLF4 and KLF6, play important roles in cellular differentiation and growth. KLF4, for example, is associated with growth arrest (Shields et al., 1996) . Interestingly, forced expression of KLF4 prevents cell proliferation by inhibiting DNA synthesis Shie et al., 2000) through activation of p21 WAF1/CIP1 promoter (Zhang et al., 2000) . KLF6 is a ubiquitously expressed Kruppel-like transcription factor whose in vivo role has not been fully characterized (Koritschoner et al., 1997; Ratziu et al., 1998) . The KLF6 gene is mutated in a subset of human prostate cancers (Narla et al., 2001) and functional studies confirm that wild-type KLF6 upregulates p21 WAF1/CIP1 in a p53-independent manner, thereby reducing cell proliferation. These data suggest that KLF6 is a tumor suppressor gene involved in human prostate cancer.
KLF2 is expressed highly in fetal and adult lungs, as well as several other organs (Anderson et al., 1995; Wani et al., 1999a) . It is absolutely required for normal embryogenesis and late stages of lung development (Kuo et al., 1997a; Wani et al., 1998 Wani et al., , 1999b . KLF2 homozygous null mice die in utero between 12.5 and 14.5 days of gestation due to severe hemorrhage, resulting from a defect of the mature blood vessel wall (Kuo et al., 1997a) . Analogous to its role in other organs, KLF2 does not appear to be a regulator of the initiation of blood vessel morphogenesis, but it is active in the late stages of blood vessel wall assembly and stabilization (Wani et al., 1998) . KLF2 also appears to play an important role in adipogenesis (Banerjee et al., 2003) , downregulating PPAR-g expression levels, a nuclear factor that is required for the adipocyte differentiation.
Additionally, KLF2 plays a role in T-cell function by preventing mature circulating cells from undergoing apoptosis (Kuo et al., 1997b, c) . Further, it is required to maintain CD4 þ or CD8 þ single-positive T cells in their quiescent state, which is characterized by decreased proliferation, reduced cell size and protein synthesis (Buckley et al., 2001) . However, the exact mechanisms by which KLF2 regulates T-cell quiescence are still unknown. The only gene targets of KLF2 identified to date are c-myc, vav and PPAR-g (Buckley et al., 2001; Denkinger et al., 2001; Banerjee et al., 2003) . However, like KLF4 and KLF6, KLF2 is likely to regulate cell proliferation in some manner.
Cell growth and proliferation are mainly controlled by mitogenic stimulation, which leads to the transition from G 1 to S phase of the cell cycle (Sherr, 1994) . This progression is regulated by the periodic activation of complexes of cyclins and cyclin-dependent kinases (cdks). Cdks are regulated by cyclin association, phosphorylation by cdk-activating kinase and association with cdk-inhibitors such as p21 WAF1/CIP1 (Sherr and Roberts, 1995; Harper and Elledge, 1996; Dynlacht, 1997) . p21
, a transcriptional target of p53 (elDeiry et al., 1993) , is a component of a complex containing cyclins, CDKs and proliferating cell nuclear antigen (Zhang et al., 1993; Chen et al., 1995) . An increased amount of p21 WAF1/CIP1 in this complex leads to an inhibition of DNA synthesis and cell cycle arrest (Harper et al., 1993) . As a cell cycle blocker, p21 WAF1/CIP1 also suppresses tumorigenicity in vivo (Yang et al., 1995) . Many known tumor suppressors, such as AP2, BRCA1, c-myc Zeng et al., 1997; Seoane et al., 2002) , KLF4 and KLF6 contribute to cell cycle arrest and growth suppression through the induction of p21 WAF1/CIP1 . Thus, p21 is a major target at the transcriptional level of cell cycle regulation.
Although KLF2 has been reported to be sufficient to program the cell quiescence in Jurkat leukemia cells (Buckley et al., 2001) , the function of KLF2 in hematologic malignancies has not been reported. However, KLF2 is likely to perform a crucial role in inhibiting leukemia cell growth (Buckley et al., 2001 ). Here we stably expressed the KLF2 protein in Jurkat leukemia cells using the tetracycline-inducible system (Gossen et al., 1995) and studied the biological consequence of KLF2 expression with regard to cell proliferation. We have found that KLF2 can inhibit Jurkat T leukemia cell growth, and that both activation and inhibitory domains of KLF2 are required for this effect. We have also demonstrated that a likely mechanism for this inhibition is direct induction of p21 WAF1/CIP1 by KLF2.
Results

KLF2 is not expressed in Jurakt T leukemia cells
To study the role of KLF2 in tumor cell growth, we first determined the levels of KLF2 expression in normal human dermal fibroblasts as well as several human cancer cell lines including Jurkat T leukemia cells, Mel-188 melanoma cells, Hep G2 hepatocellular cancer cells and SW480 colon cancer cells. RT-PCR showed that only Jurkat cells do not express the KLF2 gene, which is consistent with other reports (Buckley et al., 2001) . Previous data (Kuo et al., 1997b) indicated that only mature single-positive T lymphocytes (CD4 þ , CD8 þ ) express KLF2. Interestingly, melanoma cells, hepatocellular cancer cells and colon cancer cells have low KLF2 mRNA expression, while KLF2 is expressed at higher levels in normal dermal fibroblasts. As such, the Jurkat T leukemia cells provide a useful model to study the role of KLF2 in tumor cell growth (Figure 1 ).
Inducible KLF2 expression in Jurkat cells
Previously, we have shown that KLF2 is composed of activation, inhibitory and DNA-binding domains (Conkright et al., 2001) . To check the potential role of KLF2 as well as its activation and inhibitory domains in preventing T-cell tumor growth and to identify the downstream target genes of KLF2, we used the reverse tetracycline repressor system ( Figure 2a ) to induce the expression of KLF2 in Jurkat cells (Buckley et al., 2001) . Expression of KLF2 protein was observed using the fulllength construct or constructs where the inhibitory domain was deleted (amino acids 1-110 of KLF2, KLF2DID) or an NH 2 -terminal activation domain was deleted (amino acids 110-354, KLF2DAD) ( Figure 2b ). A HA tag was fused to the 3 0 terminus of the KLF2 zinc-finger region, and an anti-HA antibody was used to determine KLF2 expression in stable KLF2-positive Jurkat clones. A control clone, produced by transfecting Jurkat cells with an empty tetracycline-inducible plasmid, was also used. Western blot analysis was used to show protein expression of both full-length KLF2 and deletion constructs following induction with tetracycline analog doxycycline (Dox) (Figure 2b ). Before Dox treatment, KLF2 expression was undetectable in the KLF2-transfected clone and control Jurkat cells. In contrast, after 24 h of Dox treatment, KLF2s were expressed at high levels only in J/KLF2-wt-, KLF2DAD-and KLF2DID-positive clones. Similar results were obtained with multiple independently derived clones (data not shown).
KLF2 expression inhibits leukemia cell proliferation
Jurkat cells are autonomously proliferating leukemia cells derived from human acute lymphoblastic leukemia and are an excellent model for the study of molecular mechanisms of cancers. Therefore, we analysed the cell growth of Jurkat clones after induction of KLF2 expression. We found that KLF2 began to suppress T leukemia cell growth at day 3 (Figure 3) . These results are similar to other reports (Buckley et al., 2001) . This inhibition was not observed after Dox treatment of control Jurkat cells, nor in J/KLF2-DAD and J/ KLF2-DID clones. KLF2 is composed of activation and inhibitory domains, and it has been shown that the activation domain is required for the inhibition of cell growth. Interestingly, the inhibitory domain, which is not required for transcription of the globin promoter, is KLF2 as an inhibitor of leukemia cell proliferation J Wu and JB Lingrel required for inhibiting cell growth. Further, both domains are required for the reduction in 3 H-thymidine incorporation in these cells ( Figure 5 ). These results indicate that both domains are required for KLF2 to suppress Jurkat cell growth, and suggest that, while the two domains have different functional effects on gene transcription, the entire protein is required for the inhibition of leukemia cell growth.
KLF2 upregulates p21 WAF1/CIP1
To begin to understand the molecular mechanisms of KLF2-induced inhibition of leukemia cell growth, we investigated the expression levels of p21
, an important cycline-dependent kinase inhibitor. Expression of KLF2 for 48 h in Jurkat cells increased p21 induction at the protein level by KLF2 is verified by Western blot analysis ( Figure 6c ). In addition, KLF2 does not seem to alter p27 gene expression, which is another important CDK inhibitor.
KLF2 upregulates p21
WAF1/CIP1 promoter activity
To examine the mechanisms regulating the expression of p21 WAF1/CIP1 in leukemia cells, we analysed the effect of KLF2 on p21 WAF1/CIP1 promoter activity in transient transfections. Luciferase reporter constructs containing the wt p21 WAF1/CIP1 promoter were transfected into Jurkat cells in the presence or absence of KLF2. The amount of expressed KLF2 protein was routinely monitored by Western blot analysis (data not shown). H-thymidine incorporation was assessed for the last 6 h of a 48-h total period of culture Figure 5 KLF2 inhibits DNA synthesis of Jurkat T cells. J/KLF2-wt, J/KLF2-DID and J/KLF2-DAD cells were synchronized in FBS-free RPMI medium for 48 h with or without Dox induction, and were stimulated by 5% FBS for 24 h. Each group was performed in triplicate.
3 H-thymidine incorporation was assessed for the last 6 h of a 48-h total culture period In accordance with the mRNA data shown in Figure 6 , the 2.3 kb wt p21
promoter was strongly induced, up to fourfold, by KLF2 (Figure 7 ). We also examined the effect of KLF2 on the p21
promoter following transfection into Hep G2 and SW480. KLF2 activated the human p21 WAF1/CIP1 promoter luciferase reporter by fourfold to greater than 10-fold in SW 480 and Hep G2 cells (Figure 8 ).
The KLF2-responsive element is located in the Sp1-3 site within the p21 WAF1/CIP1 promoter
The p21 WAF1/CIP1 promoter contains two p53-binding sites and six Sp1 motifs in the proximal region upstream of the TATA box (Figure 9a ). p53 is a well-known transcriptional regulator of p21 WAF1/CIP1 (el-Deiry et al., 1993) . Sp1 is a Kru¨ppel-like factor that binds to GC box promoter elements, and the Sp1-binding sites in p21 WAF1/ CIP1 promoter mediate the upregulation of p21 WAF1/CIP1 (Black et al., 2001) . Since both of these transcriptional factors have been implicated in p21 WAF1/CIP1 expression, we constructed a series of p21 WAF1/CIP1 promoter luciferase plasmids, as indicated in Figure 9a . pWP60 represents the minimal p21 WAF1/CIP1 promoter. DSp1-1, DSp1-2 and DSp1-3 refer to the deletion of the first Sp1 (Sp1-1), second Sp1 (Sp1-2) and third Sp1 (Sp1-3) sites in pW124, respectively. To define the potential responsive elements of KLF2 in 2.3 kb of p21 WAF1/CIP1 promoter region, luciferase reporter constructs containing different regions of the p21 WAF1/CIP1 promoter illustrated in Figure 9a , were transfected into Jurkat cells together with a control vector in the presence or absence of KLF2. The amount of expressed KLF2 protein was monitored by Western blot analysis (data not shown). Deletion of the p53-binding site (pWP215) had no consequence on the KLF2 effect. Furthermore, removal of Sp1-binding sites 1 and 2 had little effect on promoter activation by KLF2 (Figure 9b ). As CACCC is the canonical KLF2-binding site, we performed a sitespecific mutagenesis at positions CACCC-CATGT to test whether this sole CACCC sequence in the À124 bp region of p21 WAF1/CIP1 promoter is important for KLF2 regulation. mtCACCC represents the CATGT mutant construct in the À124 bp region of p21
WAF1/CIP1 promoter. Surprisingly, mtCACCC retained the same activity as wild type, indicating that this sole CACCC in the p21
À124 promoter is not the KLF2-responsive element. This conclusion was confirmed by the DCACCC construct (pWP82) following transient transfection. The DCACCC plasmid, in which the Sp1-1, Sp1-2 and CACCC sites were deleted, still showed high induction of luciferase activity upon Dox treatment. As shown in Figure 9b , after the sequential deletion of the Sp1-binding sites, we found that the DSp1-3 construct (pWP71) did not show any induction of luciferase activity, compared to the control vector and the minimal p21 WAF1/CIP1 promoter region luciferase plasmid (pWP60). Moreover, after the Sp1-3 site was mutated in the context of the wild-type p21 WAF1/CIP1 promoter, the induction of KLF2 was abrogated.
The binding of KLF2 to the KLF2-responsive element in the p21 WAF1/CIP1 promoter was checked by performing mobility shift assays. The results of gel mobility shift assays have been shown in Figure 9d . As can be seen from the figure, there were two distinct protein-DNA complexes I and II (lane 1). These complexes were all competed with cold wt oligo (lane 2) and did not change when treated with mutated oligo (lane 3), thereby proving that these complexes are very WAF1/CIP1 promoter luciferase reporter plasmid and 2 mg b-gal control was carried out by electroporation. Cells were maintained with complete medium or complete medium with Dox for 48 h incubation in triplicates. After 48 h, cell lysates were collected for luciferase and b-gal assays Figure 8 Human hepatocellular carcinoma cells HepG2 and human colon carcinoma cells SW480 were cultured in 10% FBS DMEM. Cotransfections of 2 mg of KLF2 plasmid or control plasmid (pcDNA3.1) with 2 mg of p21 promoter luciferase reporter plasmid or pGL3 luciferase control and 0.4 mg b-gal internal control were carried out using Fugene6 transfection kit. Each group was performed in triplicate. After 48 h, cell lysates were collected for luciferase and b-gal assays. Every sample was assayed as triplicate KLF2 as an inhibitor of leukemia cell proliferation J Wu and JB Lingrel specific. A supershift band (III) can be seen with Sp1 antibody (lane 4), whereas the complexes were competed out when treated with HA antibody, suggesting that Sp1 and KLF2 are the potential proteins binding to this KLF2-responsive element. Therefore, we conclude that Sp1-3 is the KLF2-responsive element in p21 WAF1/CIP1 regulation.
Discussion
KLF2 has been shown to be required for normal embryonic development and for programming T-cell quiescence. Here we have shown that KLF2 markedly inhibits Jurkat leukemia cell growth as measured by cell number, which is consistent with previous reports (Buckley et al., 2001) . We have also shown that this reduction in cell growth is accompanied by reduced thymidine incorporation. Additionally, we have determined which domains of KLF2 are required for this effect. Our previous studies have shown that KLF2 contains an activation domain, and inhibitory domain, and a DNA-binding domain. It is unknown, however, if the inhibitory domain has any biological significance. We have found that the cell growth inhibition requires both the transactivation and inhibitory domains of KLF2, because it was not seen either after Dox treatment of Jurkat cells transfected with empty vector or in clones that lacked transcriptional activation and inhibitory activities. Previous studies have shown that at least 50 amino acids of the transactivation domain are required for T-cell quiescence (Buckley et al., 2001) , we have extended these studies and have found that the entire 110 amino-acid transactivation domain is required to specifically inhibit cell proliferation and DNA synthesis. Additionally, we have found that the inhibitory domain is required for the inhibition. Therefore, full-length KLF2 appears to be a negative regulator in leukemia cell proliferation and implicates an additional KLF family member in the inhibition of tumor cell proliferation. We also investigated whether KLF2 could activate endogenous p21 WAF1/CIP1 mRNA expression, showing that both mRNA and protein levels were elevated in Jurkat cells. Thus, KLF2 mediates some of its effects by upregulating p21 WAF1/CIP1 expression. These results strengthen the hypothesis that transcriptional activation of p21 WAF1/CIP1 by KLF2 is functionally relevant, and suggest that the gene coding p21 WAF1/CIP1 is an important downstream target of KLF2. p21 WAF1/CIP1 serves as a potent growth inhibitor of cell-cycle checkpoints (Sherr and Roberts, 1995) . Many tumor suppressors, such as AP2, BRCA1, c-myc, KLF4 and KLF6, contribute to cell cycle and growth suppression through the induction of p21 WAF1/CIP1 . Thus, p21
WAF1/CIP1 appears to be the major target of these transcriptional factors, including KLF2. promoter identified a control region of 64 base pairs (between À124 and À60) within the proximal promoter, which mediates activation of p21 WAF1/CIP1 by KLF2. The two p53-binding sites are not required for KLF2-dependent upregulation. The p21 WAF1/CIP1 promoter contains not only p53-binding sites but also several transcriptional factor responsive elements (Datto et al., 1995; Nakano et al., 1997) . One of the responsive elements is the transcriptional factor Sp1. Prior studies have shown that Sp1-dependent transcriptional effects can crossregulate the p21
promoter in response to diverse stimuli (Gartel and Tyner, 1999; Lu et al., 2000; Wang et al., 2000; Zhang et al., 2000; Lagger et al., 2003) . Interestingly, these stimuli target different signaling pathways, which target distinct Sp1 sites within the promoter. Since it has also been shown that the affinities of KLF proteins for their Sp1 sites can vary depending on spatial context (Zhang et al., 2000; Narla et al., 2001) , Sp1 sites may utilize multiple KLF proteins and their differential binding properties to integrate signal pathways.
Finally, we defined the third Sp1-binding site within the proximal promoter as the KLF2-responsive element. Two distinct protein complexes were seen in the gel mobility shift assays. These two complexes were not seen in the presence of HA antibody, thus clearly demonstrating that KLF2 directly binds to the KLF2-responsive element (Sp1-3) of the p21 WAF1/CIP1 promoter. Taken together, these data suggest that one mechanism by which KLF2 contributes to cell cycle arrest and T leukemia growth suppression is through the induction of p21
. This activation of p21 WAF1/CIP1 occurs in a p53-independent fashion, and therefore KLF2 is a promising agent for cancer therapy, since it is operative in Jurkat leukemia with mutated p53, a hallmark of numerous tumors.
In summary, we stably expressed the KLF2 protein in Jurkat leukemia cells using the tetracycline-inducible system, and have found that KLF2 can inhibit Jurkat T leukemia cell growth, and that both activation and inhibitory domains of KLF2 are required for this effect. We have also demonstrated that the likely mechanism for this inhibition is direct induction of p21 WAF1/CIP1 by KLF2. In the future, it will be important to identify additional targets of KLF2 in Jurkat leukemia cells and to understand how these targets function in conjunction with p21 WAF1/CIP1 to produce the marked change in cell proliferation. It will also be of interest to determine whether KLF2 regulates cell proliferation in other cell types.
Materials and methods
Plasmid constructs
Full-length mouse KLF2 cDNA tagged at the carboxyl terminus with hemagglutin (HA) was generated by PCR and inserted into BamH1/HindIII restriction sites of vector pBK-CMV (Stratagene), as described previously (Anderson et al., 1995; Conkright et al., 2001) . Subsequently, the insert including full-length KLF2 (KLF2-wt) with the HA tag was subcloned into the pTRE2hyg vector (Clontech) to generate Tet/KLF2-wt as a response plasmid for doxycycline induction. The KLF2-inhibitory domain and activation domain deletions fragments with the HA tag were inserted into the BamH1/ClaI site of pTRE2hyg to generate Tet/KLF2-ID and Tet/KLF2-AD, respectively.
Cell line and cell culture
The human T-cell acute lymphoblastic leukemia Jurkat tet-on cell line was acquired from Clontech and maintained in RPMI medium 1640 supplemented with 10% Tet System Approved FBS (CLONTECH), 100 mg/ml G418, 100 U/ml penicillin, 100 mg/ml streptomycin and 100 mg/ml gentamicin. Transfections of 30 mg of Tet/KLF2-wt plasmid, Tet/KLF2-ID and Tet/KLF2-AD were carried out by electroporation of 2 Â 10 7 cells with settings at 950 mF and 240 V, respectively. Stably transfected cells were selected by growth in 200 mg/ml hygromycin (Clontech) and 200 mg/ml G418 (Gibco). Single cells were generated by limited dilution. Protein expression was induced by resuspending cells at a density of 10 5 /ml in complete medium with Dox (1 mg/ml, Sigma), a derivative of tetracycline. Dox-containing medium was replaced daily during all experiments to maintain protein expression. These three stable cell lines were individually screened for high Dox inducibility by Western blotting, and named J/KLF2-wt, J/KLF2-ID and J/KLF2-ID, respectively. Human HepG2 and SW480 cells from ATCC, human normal fibroblasts and melanoma cell line (Mel-188), were cultured in DMEM with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin. Human Jurkat cells from ATCC were cultured in RPMI-1640 with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin.
Western blot analysis
Cells were lysed in 50 mM HEPES (pH7.5), 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% Triton X-100, 100mM NaF, 10 mM Na 4 P 2 O 7 , 1 mM PMSF and 1 mM Na 3 VO 4 (all chemicals from Sigma-Aldrich). Protein concentration was determined with a commercially available BCA kit (PIERCE). Samples (50 mg) were fractionated by SDS-PAGE and transferred to Immmobilon-P membrane (Millipore). After blocking, 0.5 mg/ ml rabbit polyclonal antibody raised against HA and anti-p21 (Santa Cruz) was incubated with the membrane. The secondary antibody, horse horseradish peroxidase-conjugated goat anti-rabbit (Amersham Pharmacia), was used at a 1 : 10 000 dilution. Protein-antibody interaction was visualized by chemiluminescence detection using ECL Western blotting system (Amersham Pharmacia).
wells and counting in a hemocytometer. Dead cells were determined and excluding by Trypan blue staining. Alternatively, measurement of proliferation was determined by estimating 3 H-thymidine incorporation into DNA. Jurkat clones (1 Â 10 5 ) in 24-well dishes were incubated with control medium or medium containing Dox for 48 h. Cells were pulsed with 1 mCi/ml 3 H-thymidine 6 h before harvest. After 6 h, cells were harvested on glass fiber filters using a cell harvester. Disintegrations per minute were estimated by liquid scintillation counting.
RT-PCR and multiple RT-PCR
RNA from human fibroblasts, Mel-188, Jurkat, HepG2 and SW480 cells were isolated according to the manufacturers protocol (Qiagen). RT-PCR was performed as described in the SuperScriptt First-Strand Synthesis System (Invitrogen). The primer sequences used for KLF2 were sense 5 0 -TGCCGTCC TTCTCCACTTTC-3 0 and antisense 5 0 -CTCTTGGTGTA GGTCTTGC C-3 0 . The primer sequences for GAPDH were sense 5 0 -GCTTCACCACCTTCTTG ATG-3 0 and antisense 5 0 -CACCCATGGCAAATTCCATG-3 0 . For multiple RT-PCR, the primer sequences for p21 WAF1/CIP1 were sense 5 0 -GTACC CTTGTGCCTC gctca-3 0 and antisense 5 0 -GTACCACCCAG CGGACAAGT-3 0 . For GAPDH, the primer sequences were sense 5 0 -CCAACTGCTTAGCACCCCTG-3 0 and antisense 5 0 -GACGCCTGCTTCA CCACCTT-3 0 . For p27, the primer sequences were sense 5 0 -AGAGGTGGAGAAGGGCAGCT-3 0 and antisense 5 0 -AAGAATCGTCGGTTGCAGGT-3 0 . Multiple PCR condition is 951C, 5 min; 941C, 30 s; 591C, 30 s; 721C, 1 min; 721C, 10 min; 25 cycles. -60 (pWPdel/sal, pWP60) (Nakano et al., 1997) , were kindly provided by Dr B Vogelstein, Drs H Kawamata and Dr T Fujimori, and Dr T Sakai, respectively. Sequential deletion constructs of Sp1-1, Sp1-2, CACCC and Sp1-3 in p21 WAF1/CIP1 -124, such as pWP110 (DSp1-1), pWP100 (DSp1-2), pWP82 (DCACCC) and pWP71 (DSp1-3), were generated by PCR fragments inserted into pGL3-Luc, respectively. The p21 WAF1/CIP1 -124 (pWP124) plasmid was used as a template for the generation of the CACCC mutation. This CACCC-binding site of p21 WAF1/CIP1 -124bp Luc was mutated using the QuikChange mutagenesis kit according to the manufacturer's recommendations (Stratagene). This mutation changed the wild-type sequence 5 0 -CGCGGTGGGCCGAGC-3 0 to 5 0 -CGCGGTCACCCGAGC-3 0 . p21wt construct was used as a template for generation of Sp1-3 mutation. This mutation changed the wild-type sequence 5 0 -GGCCGAGCG CGGGTCCCGCCTCCTTGAGGCGGG-3 0 to 5 0 -GGCCGA GCGCGGGTCGAGCCTCCTTGAGGCGGG.
Promoter-reporter assays
For transient transfection in suspension cells, Jurkat clones were washed and resuspended in 250 ml of fresh medium at 2 Â 10 7 /ml, and electroporated at room temperature with 40 mg of plasmid DNA, using a Gene Pulser (Bio-Rad), with settings of 240 V and 950 mF. The cells were then resuspended in fresh medium, rested for 1 h at 371C and Dox added to induce KLF2 expression. Cell lysates were prepared 48 h later, and luciferase activity was measured using a Monolightt 3010 luminometer (Pharmingen), and expressed as relative light units using a luciferase assay kit (Promega). b-Galactosidase activity was measured with a commercially available kit (Promega). For the transfection involving adherent cells, Hep G2 and SW480 cells were plated in six-well dishes at a density of 3 Â 10 5 cells/well, and transient transfections were performed the following day using FuGENE6 transfection reagent (Roche). The total amount of DNA used for the transfection assay per well was always held constant at 1 mg. The KLF2 expression plasmid was generated by subcloning KLF2 cDNA into pCDNA3.1. Promoter activity of each construct was expressed as the ratio of luciferase/b-galactoside activity. All transfections were performed in triplicate from three independent experiments.
Gel mobility shift assay
Gel shift analysis was performed with in vitro Dox-induced KLF2 (J/KLF2wt) using 5 mg of nuclear extract and 2 ng of g-[ 32 P]ATP-labeled double-stranded 19 oligonucleotide of the KLF2-responsive element in the p21 promoter, containing Sp1-3 site (5 0 -GCGGGTCCCGCCTCCTTGA-3 0 ). The binding reactions (40 ml) were carried out for 30 min at room temperature prior to gel electrophoresis. The binding buffer consisted of 50 mM Tris (pH 8.0), 100 mM KCl, 1 mM MgCl 2 , 1 mM Zn acetate, 1 mM DTT and 50% glycerol. For competition with unlabeled 19-nucleotide oligonucleotide containing either wt or mutated Sp1-3 site (5 0 -GCGGGTCGACCCTCCTTGA-3 0 ) and supershift reaction, the respective oligonucleotides and antibodies (anti-Sp1 and HA antibodies from Santa Cruz) were mixed with the nuclear extracts for 30 min before adding the radiolabeled probe. DNA-protein complexes were separated on a nondenaturing 4% (40 : 1) polyacrylamide in TGE buffer (50 mM Tris, 38 mM Glycine and 1.7 mM EDTA). The gels were dried and exposed to a phosphor imager screen. The bands were detected using a Molecular Dynamics Storm 860 phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA).
Abbreviations LKLF, lung Kru¨ppel-like factor; KLF2, Kru¨ppel-like factor 2; HA, hemagglutin; Tet, Tetracycline; Dox, Doxycycline; Multiple RT-PCR, multiple reverse transcription polymerase chain reaction; luc, Luciferase; b-gal, b-galactosidase.
